Search Results for: c

ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round. The Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and existing investors, Bios Partners, participating. Actuate will use the proceeds of the

ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING Read More »

ACTUATE THERAPEUTICS OPENS PHASE 1 / 2 CLINICAL STUDY OF 9-ING-41 IN PATIENTS WITH REFRACTORY CANCERS

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors. “Opening enrollment on our first

ACTUATE THERAPEUTICS OPENS PHASE 1 / 2 CLINICAL STUDY OF 9-ING-41 IN PATIENTS WITH REFRACTORY CANCERS Read More »

ACTUATE THERAPEUTICS SUBMITS IND APPLICATION FOR TREATMENT OF REFRACTORY CANCERS

CHICAGO, IL and FORT WORTH, TX, January 15, 2018 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical study of 9-ING-41, Actuate’s lead agent – a proprietary GSK-3β inhibitor. This initial IND

ACTUATE THERAPEUTICS SUBMITS IND APPLICATION FOR TREATMENT OF REFRACTORY CANCERS Read More »